A ElNaggar
Overview
Explore the profile of A ElNaggar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ElNaggar A, Zhang N, Scalise C, Sirard C, Kagey M, Vaena D, et al.
Gynecol Oncol Rep
. 2022 May;
39:100904.
PMID: 35531363
Targeted therapies are being increasingly used in clinical practice and trials. However, tumor heterogeneity among sites of metastatic disease can occur creating a conundrum when utilizing biomarker directed therapies. Here...
2.
AbdelHafeez M, Reda A, ElNaggar A, El-Zeneiny H, Mokhles J
Arch Gynecol Obstet
. 2019 Aug;
300(5):1271-1277.
PMID: 31435774
Background: Chronic pelvic pain (CPP) is a frequent presenting symptom in gynaecology outpatient clinics. Neuromodulator pharmacological agents could be an option for treatment based on its efficacy in treating chronic...
3.
Lai S, Batsakis J, Ordonez N, Luna M, Goepfert H, ElNaggar A
Oncol Rep
. 2011 May;
2(6):1115-20.
PMID: 21597865
p53 is the most frequently altered suppressor gene in human cancers. The genotypic and corresponding phenotypic abnormalities of this gene in head and neck squamous cell carcinoma (HNSCC) remain undefined....
4.
Eissa S, Wahed M, Ismail A, Amer K, Khalifa A, ElNaggar A
Oncol Rep
. 2011 May;
4(2):443-5.
PMID: 21590076
Hepatocellular carcinoma (HCC) is the most common and aggressive form of primary liver tumors. The evolution and the putative association of this neoplasm with hepatic cirrhosis and liver cell dysplasia...
5.
Cervantes M, Zhou H, Sahin A, Dhingra K, Valero V, Ordonez N, et al.
Int J Oncol
. 2011 May;
6(5):955-62.
PMID: 21556624
Correlation of p53 gene/protein alterations with incidence of oncogene amplification, a potential marker of prognosis, was evaluated in 26 fresh breast cancer samples. p53 gene was analyzed by SSCP and...
6.
Aydin A, ElNaggar A, Robertson L, Keating M, Huh Y
Int J Oncol
. 2011 May;
7(6):1433-6.
PMID: 21552984
Chronic lymphocytic leukemia (CLL) is typically an indolent lympho-proliferative disorder. Its clinical course is notable for marked heterogeneity, but in a subset of patients, the disease pursues a relatively rapid...
7.
Kemp B, Silva E, ElNaggar A
Int J Oncol
. 2011 May;
7(3):661-5.
PMID: 21552888
We performed interphase in situ hybridization (ISH) for chromosomes 12 and X and now cytometric DNA analysis on seven juvenile granulosa cell tumors to verify this observation and correlate the...
8.
Xu X, Stier U, Rosewicz S, ElNaggar A, Lotan R
Int J Oncol
. 2011 May;
8(3):445-51.
PMID: 21544381
Retinoids restore normal cell growth and differentiation in malignant cells and are considered as potential therapeutic agents. Before using retinoids for the treatment of pancreatic cancer it is important to...
9.
Rosmorduc O, Wendum D, Arrive L, ElNaggar A, Ennibi K, Hannoun L, et al.
Gastroenterol Clin Biol
. 2008 Apr;
32(3):321-7.
PMID: 18403150
Ferroportin is a putative transmembrane channel involved in the exit of iron out of the enterocytes, the macrophages and the hepatocytes. Mutations in the human gene coding ferroportin have been...
10.
REARDON J, Levine S, Peske G, ElNaggar A, Normandin E, Clark B, et al.
J Cardiopulm Rehabil
. 1995 Jul;
15(4):277-82.
PMID: 8542533
Purpose: Although cardiac and pulmonary rehabilitation are frequently considered together, differences in the two populations have not been evaluated adequately. Methods: This study compared patients who were referred to outpatient...